BioInvent: Approval for New Study Start
Research Note
2020-12-21
10:35
Redeye sees the CTA approval for oncolytic virus project BT-001 as a sign of continued good momentum for BioInvent. We adjust our valuation for the recent reverse share split, rendering a base case of SEK 75.
NE
Niklas Elmhammer
Disclosures and disclaimers